News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
768,739 Results
Type
Article (52918)
Company Profile (695)
Press Release (715126)
Section
Business (225234)
Career Advice (2969)
Deals (38716)
Drug Delivery (115)
Drug Development (87275)
Employer Resources (185)
FDA (17465)
Job Trends (16644)
News (380285)
Policy (36602)
Tag
Academia (2765)
Alliances (54973)
Alzheimer's disease (1371)
Approvals (17402)
Artificial intelligence (185)
Bankruptcy (391)
Best Places to Work (12389)
Biotechnology (477)
Breast cancer (209)
Cancer (1583)
Cardiovascular disease (132)
Career advice (2496)
Cell therapy (343)
Clinical research (69717)
Collaboration (600)
Compensation (312)
COVID-19 (2778)
C-suite (142)
Data (1496)
Diabetes (201)
Diagnostics (6660)
Earnings (92384)
Employer resources (160)
Events (123816)
Executive appointments (489)
FDA (18251)
Funding (534)
Gene therapy (241)
GLP-1 (724)
Government (4767)
Healthcare (20241)
Infectious disease (2882)
Inflammatory bowel disease (126)
Interviews (551)
IPO (17519)
Job creations (4740)
Job search strategy (2081)
Layoffs (496)
Legal (9226)
Lung cancer (237)
Manufacturing (241)
Medical device (14304)
Medtech (14309)
Mergers & acquisitions (21418)
Metabolic disorders (552)
Neuroscience (1763)
NextGen: Class of 2025 (7345)
Non-profit (4814)
Northern California (1901)
Obesity (315)
Opinion (249)
Patents (140)
People (62591)
Pharmaceutical (142)
Phase I (21639)
Phase II (30578)
Phase III (22962)
Pipeline (626)
Postmarket research (2897)
Preclinical (9297)
Radiopharmaceuticals (259)
Rare diseases (308)
Real estate (6859)
Regulatory (24271)
Research institute (2498)
Resumes & cover letters (469)
Southern California (1646)
Startups (4132)
United States (17548)
Vaccines (664)
Weight loss (240)
Date
Today (138)
Last 7 days (912)
Last 30 days (2249)
Last 365 days (37406)
2025 (1486)
2024 (37708)
2023 (42379)
2022 (53733)
2021 (58442)
2020 (57112)
2019 (50294)
2018 (38174)
2017 (35696)
2016 (35940)
2015 (41956)
2014 (36358)
2013 (31681)
2012 (33501)
2011 (33764)
2010 (32154)
Location
Africa (955)
Arizona (221)
Asia (44828)
Australia (7470)
California (4414)
Canada (1558)
China (371)
Colorado (200)
Connecticut (223)
Europe (99734)
Florida (605)
Georgia (148)
Illinois (463)
Indiana (255)
Maryland (722)
Massachusetts (3521)
Michigan (201)
Minnesota (337)
New Jersey (1237)
New York (1234)
North Carolina (912)
Northern California (1901)
Ohio (161)
Pennsylvania (1019)
South America (1378)
Southern California (1646)
Texas (641)
Utah (126)
Washington State (461)
768,739 Results for "merck and company inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pipeline
JPM25 Day Two: Roche, Amgen, Merck, Lilly and Biogen
JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year.
January 15, 2025
·
4 min read
·
Tristan Manalac
FDA
2024 Ends With Greenlights for Merck’s PAH Drug in UK and BMS’ Opdivo Injection in US
Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s greenlight for an injectable formulation of BMS’s cancer blockbuster.
January 2, 2025
·
2 min read
·
Kate Goodwin
Manufacturing
Merck Snaps Up WuXi Biologics Facility in Ireland for $500M
The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s manufacturing operations in Ireland.
January 6, 2025
·
1 min read
·
Annalee Armstrong
Clinical research
Merck’s Subcutaneous Keytruda Meets Expectations in Phase III
Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster goes off patent in 2028.
November 19, 2024
·
2 min read
·
Annalee Armstrong
GLP-1
Merck Joins Obesity Pill Race With Up to $2B Hansoh Deal
The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk and Roche.
December 18, 2024
·
2 min read
·
Tristan Manalac
Vaccines
CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64
The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.
October 24, 2024
·
2 min read
·
Tristan Manalac
Earnings
Merck Lowers Full-Year Sales Guidance Despite Strong Overall Q3 Results
Offsetting Merck’s growth in the third quarter were disappointing revenues from its HPV vaccine Gardasil and type 2 diabetes pill Januvia, with the company on Thursday narrowing its 2024 sales and adjusted profit outlooks.
October 31, 2024
·
2 min read
·
Tristan Manalac
Lymphoma
Merck Touts 100% Complete Response Rate for Anti-ROR1 ADC as First-Line Lymphoma Treatment
Analysts called the data “very competitive” but raised questions about safety. Merck gained ownership of the ADC when it acquired VelosBio in November 2020 for $2.75 billion.
December 9, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Merck’s GARDASIL® Receives Expanded Approval for Males in China
January 8, 2025
·
7 min read
Collaboration
Merck Hops Onto PD-1/VEGF Train, Committing up to $3B Plus in LaNova Deal
Despite recent enthusiasm around the PD-1/VEGF space, BMO Capital Markets analyst Evan Seigerman noted that Merck’s pact with LaNova Medicines is more “conservativism” on the pharma’s part than confirmatory of recent data in the drug class.
November 14, 2024
·
2 min read
·
Tristan Manalac
1 of 76,874
Next
